Immunotherapy for Resectable Locally Advanced Esophageal Carcinoma

CONCLUSIONS: Outside of clinical trials, immunotherapy for resectable esophageal carcinoma is limited to the adjuvant setting. Phase III trials investigating neoadjuvant and perioperative immunotherapy are now underway and will provide much-needed data on survival that may ultimately lead to practice-changing recommendations.PMID:38408631 | DOI:10.1016/j.athoracsur.2024.02.021

Source: The Annals of Thoracic Surgery - February 26, 2024 Category: Cardiovascular & Thoracic Surgery Authors: Cameron N Fick Elizabeth G Dunne Smita Sihag Daniela Molena Samuel L Cytryn Yelena Y Janjigian Abraham J Wu Stephanie G Worrell Wayne L Hofstetter David R Jones Katherine D Gray Source Type: research